HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Anatoxin a(S)

HCID 114989
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
103170-78-1
Standard SMILES
COP(=O)(O)ON1C(N)=NC[C@@H]1CN(C)C
InChIKey
FYXHGVMFJYHPFX-ZCFIWIBFSA-N
Molecular formula
C7H17N4O4P
Average molar mass
252.21 g/mol
Monoisotopic mass
252.09874203

Overview

Anatoxin a(s) is a monoalkyl phosphate.

Names & identifiers

Preferred name
Anatoxin a(S)
IUPAC
[(5S)-2-amino-5-[(dimethylamino)methyl]-4,5-dihydroimidazol-1-yl] methyl hydrogen phosphate
English name
ANATOXIN-A(S)
Molecular formula
C7H17N4O4P
Molecular weight
252.21

Names & synonyms

Anatoxin a(s)Anatoxin-A(S)Guanitoxin103170-78-1Antx-a(sANTX-A(S)ANATOXIN A(S) [MI]4258P76E76DTXSID20897217[(5S)-2-amino-5-[(dimethylamino)methyl]-4,5-dihydroimidazol-1-yl] methyl hydrogen phosphate(5S)-2-Amino-1-((hydroxymethoxyphosphinyl)oxy)-N,N-dimethyl-4,5-dihydro-1H-Imidazole-5-methanamine1H-Imidazole-5-methanamine, 2-amino-4,5-dihydro-1-((hydroxymethoxyphosphinyl)oxy)-N,N-dimethyl-, (5S)-
Show more names
PHOSPHORIC ACID, MONO((5S)-2-AMINO-5-((DIMETHYLAMINO)METHYL)-4,5-DIHYDRO-1H-IMIDAZOL-1-YL) MONOMETHYL ESTERPhosphoric acid, mono[(5S)-2-amino-5-[(dimethylamino)methyl]-4,5-dihydro-1H-imidazol-1-yl] monomethyl ester(((5R)-5-((dimethylamino)methyl)-2-iminoimidazolidin-1-yl)oxy)(methoxy)phosphinic acid{[(5R)-5-[(dimethylamino)methyl]-2-iminoimidazolidin-1-yl]oxy}(methoxy)phosphinic acid((5S)-2-amino-5-((dimethylamino)methyl)-4,5-dihydroimidazol-1-yl) methyl hydrogen phosphateRefChem:558023DTXCID301326608DTXCID401021623

Database identifiers

CAS
103170-78-1、92142-32-0
PubChem CID
114989

Properties

Computed structural propertiesFilling in

XLogP
-4.4
Topological polar surface area
101 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
6
Rotatable bonds
5
Heavy atoms
16
Formal charge
0
Complexity
322

Physicochemical properties

EWG's Food Scores
1 · 1
FDA UNII
4258 P76E76 · 4258P76E76
Toxicity
50 i.p · Stable in neutral or acid conditions. LD50 i.p. in mice: 20 mg/kg (Carmichael)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Treatment · 1 item

If the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.

Health Effects · 1 item

Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Metabolism of organophosphates occurs principally by oxidation, by hydrolysis via esterases and by reaction with glutathione. Demethylation and glucuronidation may also occur. Oxidation of organophosphorus pesticides may result in moderately toxic products. In general, phosphorothioates are not directly toxic but require oxidative metabolism to the proximal toxin. The glutathione transferase reactions produce products that are, in most cases, of low toxicity. Paraoxonase (PON1) is a key enzyme in the metabolism of organophosphates. PON1 can inactivate some organophosphates through hydrolysis. PON1 hydrolyzes the active metabolites in several organophosphates insecticides as well as, nerve agents such as soman, sarin, and VX. The presence of PON1 polymorphisms causes there to be different enzyme levels and catalytic efficiency of this esterase, which in turn suggests that different individuals may be more susceptible to the toxic effect of organophosphate exposure.

Additional notes

DefinitionChEBI: Anatoxin a(s) is a monoalkyl phosphate.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID
DTXSID20897217
ChEBI
CHEBI:188038
UNII
4258P76E76
EC Number
635-603-3
Nikkaji
J900.907H
Toxicity Summary · 1 item

Anatoxin-a(s) is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.

Signs and Symptoms · 1 item

Symptoms of low dose exposure include excessive salivation and eye-watering. Acute dose symptoms include severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Hypertension, hypoglycemia, anxiety, headache, tremor and ataxia may also result.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Safety data

Toxicity
Stable in neutral or acid conditions. LD50 i.p. in mice: 20 mg/kg (Carmichael)